H.C. Wainwright Thinks Presbia PLC’s Stock is Going to Recover

By Carrie Williams

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Presbia PLC (NASDAQ: LENS) yesterday and set a price target of $12. The company’s shares closed yesterday at $2.69, close to its 52-week low of $2.28.

According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -7.6% and a 34.7% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as RegeneRx Biopharmaceuticals Inc, Biospecifics Technologies Corp, and Stemline Therapeutics Inc.

Presbia PLC has an analyst consensus of Moderate Buy, with a price target consensus of $12.

The company has a one year high of $5.50 and a one year low of $2.28. Currently, Presbia PLC has an average volume of 18.64K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Presbia Plc operates as an ophthalmic device company. It develops and markets a proprietary optical lens implant for treating presbyopia, the age-related loss of the ability to focus on near objects. The company was founded on February 2, 2014 and is headquartered in Dublin, Ireland.